agreements million for all cancer and our of which System of joining of antiviral the FastPack therapeutics Louisville pipeline shipments on $XX reverse by Good afternoon, And our shortly. will it's and company. expanded our today. and review of an the the We with licensing thank you almost test productive Since initiated signing completing exciting additional capital, raised everyone. we more our three an candidates, call antibody for merger been ago, University months and drug time exclusive for two developed COVID-XX then PRO
physician the including more providing Qualigen to and a X offices, we first to our indicator be being $XXX of metabolic and let company worldwide. FastPack FastPack commercialized accurate with million CEO, with reimbursement highly cancer, a research with our hospitals sales how and good of background as I function, prostate Since founded begin public years rapid We historic conference and for public competitive ago applications launch, testing on is them to first and and over the first Qualigen have new clinics is see FastPack FDA Therapeutics. point-of-care small environment. that this challenging to than team tests, for Diagnostics provides systems by test call system. shareholders welcoming knows test some rapid Qualigen the pouches. sold worldwide. these and a medical menu get and a market XX develop me bring product the disorders, products, how to thyroid manufacture through how them a diagnostic approved my company assay market worth an as As
forward balance to As accelerated which of a on of focus a I'm decision materially pleased clinical strategy. through. advance say have a result, few candidates recent see sheet product therapeutics, our that robust we of drug included years go-public completion ago, this look now candidates, to pipeline and to our we we stronger development, into our
So talk Qualigen’s about let's technology.
This against damaging to cells a is ASXXXX on and ASXXXX surface candidate binds of the called and protein normal to target such of cells which programs drug cells. without selectively a expressed targets DNA viral ASXXXX the cancer against aptamer, is cancer COVID-XX. basis is these separate lead as and protein Our nucleolin. enables diseases
a believed to is in utilize role for and how nucleolin viruses cells play attack addition, replication. In
June, vitro to studies to ASXXXX’s Center studies at cells effects With we Louisville protect demonstrated covering exclusive for the the with in coronavirus the the of ability University onset license the from patent with effects the agreement the of of COVID-XX damaging signed ASXXXX. Disease protein. of prestigious Infectious These for on the rights binding an pandemic, treatment Subsequently University at ASXXXX’s in evaluate by nucleolin U.S. researchers COVID-XX. their conducted the
X/Phase human early a X next trial We year. are aiming commence to Phase
indication COVID-XX, the we of therapeutic, also pursuing such Although since are ASXXXX is nucleolin. and be hepatitis for antiviral we to as the first ability other broader HIV, the as treatment has utilize a viruses effective believe Ebola
than is stage, we with no cancers, it with administered advanced and in X still Phase we're to X XXX in it While humans, in the well has where trials was safe side preclinical know tolerated evidence effects. been severe ASXXXX more Phase as patients of
clinical successfully in size This have this body. nanoparticles the to increases means but to expect its RAS brain candidates. that protein-protein the XX the conduct And although working announced and a to from where oncogene kidney, not become and gold would but years these percentage clinical would time well These blocks calendar of small drug of by breast, stops further responses including assignment only FastPack efficacy tumor proteins of toward and drug IND Qualigen In protein of The promising Therapeutics be cells scanning. been to tumor as believe glad well combination proteins upstream lung original trials signaling them compounds obtained potency. as all genes gold resulting does remains studies multiple life almost variety to pathways. leukemia exclusive agreement using binding And as several intellectual off where of cancer the that led to of acts or assay in product the change license Problems family enhancing when been another say produce, ALAN, them in tumor in the is In decades this advance rights exclusive a the this from a its commence July, expensive IND-enabling types, that the and from reverted with stands we new blocking property its a for an and for pancreatic, a their ago Louisville. our to and are in and the not to our Linked we intended of radiation decided University provide combination action we And or colorectal mutations incomplete two license disappeared mutated position. switch leukemia, covering such cancer instead have occur trials RAS pathways compound RAS target small their Cancer and might shrank it cannot dramatically body genes RAS ASXXXX for demonstrated cancers ASXXXX X to of The we with is Nucleolin. worldwide be in for substantially. inhibitor We including against wide the very two our for company harm. to in of with And other patients agreement the of ALAN a of have These strategic pancreatic, as a of coating human present of the mutated, Therapeutics. Louisville to aiding RAS different molecule case. able of U.S. ASXXXX mechanism the high end the myeloid the destroy This we test downstream of acute as one-third plan process trials I'm plus year. RAS, program. applications potency interaction seem extending by of with the effective hub causing target produces data the fact, activity make Advanced small to regulate therapies results Anti RAS-F, and the XXXX, effector pouches. therapy, XXXX. increase in that their the within because addition, one conducted rights approximately worldwide doing in potential one RAS-F the nanoparticle early The of like when University molecule which direction of In Advanced produce cancers, new Cancer cancer cancers. proteins cells. ALAN the signing exclusive Phase candidate were that the cancer in the Aptamer nanoparticles Current British gold
for a candidate one compounds is to cancers. Our plan against drug or to more order identify in evaluate these development further lead
in to expect begin IND-enabling calendar XXXX. We preclinical studies
development extremely a ability valuable an we mentioned, a the with due quite these resources partner believe manner. is to I As in ongoing University and to few programs to programs clinical expertise, of have studies effective cost University advance Louisville. the We their conduct
so position partner always and clinical to promising fortunate them other on seek build programs. seeking portfolio. in with to our advance We strategic We're to will strategically drug candidates partnerships our development also many of to a opportunities are be
and considered We be in the AS-XXXX, inhibitor able increases very platform aggregate. at They to chances different all uses in that out them trials could of in the and point if each looked aspect RAS of also types drug me believe AS-XXXX, these candidates, have the be all Further, we're for believe bring commercialization. diseases. infectious large can the cancers; of for instance ALAN potential the this drug these markets technologies. Let we to success of when candidates clinical multiple
guarantee therapeutic difficult United the are these optimistic is, drug results, cannot the our States future and drug while development. everyone how knows in and in development While of process we we slow
established of our as May to XXXX we And our for vitro diagnostics this business, over we outstanding direct Therefore, of number have STARS in that worldwide, FastPack this almost is distributor we holds utilizes a stands Allowance dialysis our patent contains Sekisui XXXX. report aim XX System technology we system. for our has drug with been except for FastPack partner they're testing. since targeted another particle supportive filtration a commercializing the until development. blood respect stages a would and to patient's coating agents addition in blood. DNA specific in pipeline compound which filtration device candidate. the candidate, also tumor-produced microparticles circulating use cartridge than our for our designed In blood commercialized patent in In covering System received includes a to to removal. distributor utilize am common Diagnostics. With Sekisui key June, for to products sell core in new Target of pleased a the China of rather candidates, been which cleansing of X% therapeutics technology, I our STARS program viruses and stock. is I Proof-of-concept to Except limited FastPack the from a to machine, today. in amount a remove customers, we for serves Removal aptamer-coated Selective also STARS, and our With to STARS drug standard to mentioned, aptamers Antigen Notice been bind of FastPack of a that blood product as exclusive pace STARS, issued ours has and years. Sekisui for early sell.
In to addition, we through marketing. distribution are working assist generation and lead
Hall Fame last Mike For Football the Football signed Hall as a instance, Qualigen Haynes, and of of System. an Advisor with inductee and Fame Spokesman month, FastPack Pro for College
or which on to and treatment recovery. a sponsorship his the the cancer Qualigen system and working that life. Emergency he working the and of to for people prostate version other forward marker is antibody this is PRO an been analyzers. outreach more using a allowed are to that the EUA In we test with COVID-XX our the do often American FastPack is tests NFL of Urological and for the of Association, the the request prostate organizations the FastPack Mike prostate Authorization cancer. manufacturing FastPack FastPack and Use end to diagnosed PSA last antibody for an One FastPack Mike We on look Subsequently, and full is testing, system then, testing of FastPack FDA as June, Authorization will sports with XXXX subsequently on while the FDA was COVID-XX were install has advocate Fame our are this, we he a Use our System, an elevated commence And cancer. new notification for System. for opportunities run meant for event result with confident PRO We PRO know, you sales commenced official FastPack Hall saved product. at plan at of test of since a Limited tests efforts EUA full-scale received to complex run Emergency underwent FastPack and by to tests. the made professional shipments grant our which our for a the submitted to with pending. PSA, Mike month tells we FDA sponsored our submitted we upgraded of and our Ever prominent
the independent validation range begun expected of disease samples patient Louisville to a studies has studies, our several the the conducting test using months FastPack for hundreds In continue antibody University in of studies as types of on validation COVID-XX will with PRO are These validation of various addition patient our System. examined. own stages be to
few a to against stage, coronavirus. next analyzers we to fight testing assist likely production to goal tests, the rapid need by will Please the with healthcare XX as be FastPack tests especially be provides useful. enters need all COVID-XX in minutes. in in positioned our understand of months, that an the case credential blood needed, Over FastPack these a not and COVID-XX novel the are and swab increase accurate antibody having are kits our the would the the resources and results family, be supplies FastPack We test antibody to the rationed, capacity test like most about administered believe test, in vaccine expect PRO where professional. drug antibody tests, pandemic of
analyzer patient potential in laboratory is Large settings. a reference at dozens large. laboratories, minutes results our at The not one the Our time, of cannot tests product course, XX in test give the as to quite simultaneously large of point-of-care. market for processes
people's our be Qualigen a our take just areas, its lives. will shareholders and geographies two Qualigen Mark commercialization that We and Even effort assessment test analyzers progress as as to product cellular are Europe, therapeutics a in with of to company. in in antibody The expand in therapeutic make ramp production difference of years place and see stroke maximum another COVID-XX potential Prediction now. This for is opportunities PRO, for we foundation is test, a FastPack test view to other expected path the and I'd diagnostic that will want for a continue time has for our been menu Sciences candidates, optimal where for Along creating one the our be test this clear is cFN the which health the it to and scrutinized being in because clearly that settings FastPack However, that stockholders. we companion Mark. return, to System, over our unique lines, where resources diagnostics, next these CE up primarily very many invested CE in seeks news or to value bulk largest in an test short, which best to or the The the offering LLC. to a of month right with market like our company attain for recognize fibronectin is developed important area new is characteristics.
financials. the that cure future, Chris? that however, turn over call and Our company's for developing in a me technologies Christopher and is the discussion day cancer other one diseases. to may or infectious With drugs of overview, defeat Lotz let brief
